Shifting Medicine Forward
Drawing on a deep understanding of the underlying causes, Ichnos Sciences is pursuing truly disease-centric therapies in oncology. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.
Our path toward disease-centric therapies
Oncology Pipeline
| Candidate | Target | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| ISB 1342 | CD38 x CD3 BEAT® 1.0 bispecific antibody |
Phase 1 Enrolling | ||||
| ISB 1442 | CD38 x CD47 BEAT® 2.0 bispecific antibody | IND-Enabling Studies | ||||
| ISB 2001 | TREAT™ trispecific antibody | Discovery | ||||
| ISB 2004 | BEAT® 2.0 bispecific antibody | Discovery | ||||
| ISB 2005 | TREAT™ trispecific antibody | Discovery |
oncology pipeline
-
Compound:ISB 1342Target:CD38 x CD3 BEAT® 1.0
bispecific antibodyIndication:Relapsed/Refractory Multiple Myeloma -
Status:Phase 1 Enrolling
-
Compound:ISB 1442Target:CD38 x CD47 BEAT® 2.0 bispecific antibodyIndication:Relapsed/Refractory Multiple Myeloma
-
Status:IND-Enabling Studies
-
Compound:ISB 2001Target:TREAT™ trispecific antibodyIndication:Hematologic Malignancies
-
Status:Discovery
-
Compound:ISB 2004Target:BEAT® 2.0 bispecific antibodyIndication:Hematologic Malignancies/ Solid Tumors
-
Status:Discovery
-
Compound:ISB 2005Target:TREAT™ trispecific antibodyIndication:Hematologic Malignancies
-
Status:Discovery
Phase:
Phase:
Phase:
Phase:
Phase:
BEAT®: Bispecific Engagement by Antibodies based on the T-cell receptor
TREAT™: Trispecific Engagement by Antibodies based on the T-cell receptor
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.
Out-licensing opportunities available for biologics in autoimmune diseases.
View Career Opportunities
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
